Adjuvant Chemotherapy in Pancreatic Cancer View Full Text


Ontology type: schema:Chapter     


Chapter Info

DATE

2010

AUTHORS

Paula Ghaneh , John P. Neoptolemos , David Cunningham

ABSTRACT

:Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or in the liver. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using either 5-fluorouracil/folinic acid (5FU/FA) or gemcitabine and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet, that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The recent RTOG 9704 combination study did not demonstrate a survival difference between a 5FU based regimen compared with a gemcitabine based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA based on the results from the ESPAC-1 study. Gemcitabine also confers a disease free survival advantage when given as adjuvant therapy in patients who have undergone pancreatic resection. The survival advantage associated with chemotherapy is supported by an individual patient data meta-analysis and further meta-analyses.The accumulation of level 1 evidence has now confirmed that the standard of care for adjuvant therapy is post operative chemotherapy using either 5FU/FA or gemcitabine. Ongoing trials will address which agents are the most effective and which patients will benefit the most. More... »

PAGES

1051-1077

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/978-0-387-77498-5_43

DOI

http://dx.doi.org/10.1007/978-0-387-77498-5_43

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1041488623


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Oncology and Carcinogenesis", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ghaneh", 
        "givenName": "Paula", 
        "id": "sg:person.07372440237.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK", 
          "id": "http://www.grid.ac/institutes/grid.415970.e", 
          "name": [
            "Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neoptolemos", 
        "givenName": "John P.", 
        "id": "sg:person.0750565077.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The Royal Marsden Hospital, London and Surrey, UK", 
          "id": "http://www.grid.ac/institutes/grid.424926.f", 
          "name": [
            "The Royal Marsden Hospital, London and Surrey, UK"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Cunningham", 
        "givenName": "David", 
        "id": "sg:person.01320161130.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16"
        ], 
        "type": "Person"
      }
    ], 
    "datePublished": "2010", 
    "datePublishedReg": "2010-01-01", 
    "description": "Abstract:Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease and only 10\u201315% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or in the liver. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using either 5-fluorouracil/folinic acid (5FU/FA) or gemcitabine and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet, that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The recent RTOG 9704 combination study did not demonstrate a survival difference between a 5FU based regimen compared with a gemcitabine based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA based on the results from the ESPAC-1 study. Gemcitabine also confers a disease free survival advantage when given as adjuvant therapy in patients who have undergone pancreatic resection. The survival advantage associated with chemotherapy is supported by an individual patient data meta-analysis and further meta-analyses.The accumulation of level 1 evidence has now confirmed that the standard of care for\u2009adjuvant therapy is post operative chemotherapy using either 5FU/FA or gemcitabine. Ongoing trials will address which agents are the most effective and which patients will benefit\u2009the most.", 
    "genre": "chapter", 
    "id": "sg:pub.10.1007/978-0-387-77498-5_43", 
    "isAccessibleForFree": false, 
    "isPartOf": {
      "isbn": [
        "978-0-387-77497-8", 
        "978-0-387-77498-5"
      ], 
      "name": "Pancreatic Cancer", 
      "type": "Book"
    }, 
    "keywords": [
      "level 1 evidence", 
      "adjuvant therapy", 
      "survival advantage", 
      "pancreatic cancer", 
      "combination therapy", 
      "disease-free survival advantage", 
      "ESPAC-1 trial", 
      "large randomized trials", 
      "post-operative chemotherapy", 
      "standard of care", 
      "individual patient data", 
      "clear survival advantage", 
      "curative surgery", 
      "adjuvant setting", 
      "adjuvant chemoradiation", 
      "combination chemoradiation", 
      "GITSG study", 
      "chemoradiation regimen", 
      "operative chemotherapy", 
      "adjuvant chemotherapy", 
      "advanced disease", 
      "most patients", 
      "pancreatic resection", 
      "randomized study", 
      "ongoing trials", 
      "randomized trials", 
      "systemic disease", 
      "poor prognosis", 
      "cancer death", 
      "folinic acid", 
      "survival differences", 
      "chemoradiation", 
      "chemotherapy", 
      "patients", 
      "gemcitabine", 
      "therapy", 
      "combination studies", 
      "resection", 
      "major cause", 
      "patient data", 
      "cancer", 
      "trials", 
      "regimen", 
      "surgery", 
      "disease", 
      "EORTC", 
      "recurrence", 
      "prognosis", 
      "follow", 
      "liver", 
      "study", 
      "FA", 
      "care", 
      "death", 
      "evidence", 
      "survival", 
      "intervention", 
      "cause", 
      "agents", 
      "setting", 
      "differences", 
      "accumulation", 
      "results", 
      "acid", 
      "use", 
      "data", 
      "standards", 
      "advantages", 
      "observations", 
      "justification"
    ], 
    "name": "Adjuvant Chemotherapy in Pancreatic Cancer", 
    "pagination": "1051-1077", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1041488623"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/978-0-387-77498-5_43"
        ]
      }
    ], 
    "publisher": {
      "name": "Springer Nature", 
      "type": "Organisation"
    }, 
    "sameAs": [
      "https://doi.org/10.1007/978-0-387-77498-5_43", 
      "https://app.dimensions.ai/details/publication/pub.1041488623"
    ], 
    "sdDataset": "chapters", 
    "sdDatePublished": "2022-11-24T21:15", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20221124/entities/gbq_results/chapter/chapter_277.jsonl", 
    "type": "Chapter", 
    "url": "https://doi.org/10.1007/978-0-387-77498-5_43"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/978-0-387-77498-5_43'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/978-0-387-77498-5_43'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/978-0-387-77498-5_43'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/978-0-387-77498-5_43'


 

This table displays all metadata directly associated to this object as RDF triples.

140 TRIPLES      21 PREDICATES      94 URIs      87 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/978-0-387-77498-5_43 schema:about anzsrc-for:11
2 anzsrc-for:1112
3 schema:author N5b4b3db1102546fdb88a4a8b478fc301
4 schema:datePublished 2010
5 schema:datePublishedReg 2010-01-01
6 schema:description Abstract:Pancreatic cancer is one of the major causes of cancer death. Most patients present with advanced disease and only 10–15% of patients can undergo resection. Survival after curative surgery is poor, as recurrences occur either locally or in the liver. Adjuvant therapy has been employed in large randomized trials to treat systemic disease and hopefully improve the poor prognosis. Chemoradiation, chemotherapy using either 5-fluorouracil/folinic acid (5FU/FA) or gemcitabine and combination therapy have all been used in the adjuvant setting.The results of the EORTC and ESPAC-1 trials have revealed that there is no survival advantage associated with adjuvant chemoradiation following resection for pancreatic cancer compared to no chemoradiation. There is no level 1 evidence, as yet, that chemoradiation is superior to chemotherapy alone following surgery. Justification for the use of combination chemoradiation with follow on chemotherapy is based on the results of an underpowered 1987 GITSG study, which closed prematurely and compared intervention to observation. The recent RTOG 9704 combination study did not demonstrate a survival difference between a 5FU based regimen compared with a gemcitabine based chemoradiation regimen. There is no completed randomized study comparing chemotherapy versus combination therapy.There is a clear survival advantage with adjuvant 5FU/FA based on the results from the ESPAC-1 study. Gemcitabine also confers a disease free survival advantage when given as adjuvant therapy in patients who have undergone pancreatic resection. The survival advantage associated with chemotherapy is supported by an individual patient data meta-analysis and further meta-analyses.The accumulation of level 1 evidence has now confirmed that the standard of care for adjuvant therapy is post operative chemotherapy using either 5FU/FA or gemcitabine. Ongoing trials will address which agents are the most effective and which patients will benefit the most.
7 schema:genre chapter
8 schema:isAccessibleForFree false
9 schema:isPartOf Nd080dc66b07246a38cdf4daf44787a35
10 schema:keywords EORTC
11 ESPAC-1 trial
12 FA
13 GITSG study
14 accumulation
15 acid
16 adjuvant chemoradiation
17 adjuvant chemotherapy
18 adjuvant setting
19 adjuvant therapy
20 advanced disease
21 advantages
22 agents
23 cancer
24 cancer death
25 care
26 cause
27 chemoradiation
28 chemoradiation regimen
29 chemotherapy
30 clear survival advantage
31 combination chemoradiation
32 combination studies
33 combination therapy
34 curative surgery
35 data
36 death
37 differences
38 disease
39 disease-free survival advantage
40 evidence
41 folinic acid
42 follow
43 gemcitabine
44 individual patient data
45 intervention
46 justification
47 large randomized trials
48 level 1 evidence
49 liver
50 major cause
51 most patients
52 observations
53 ongoing trials
54 operative chemotherapy
55 pancreatic cancer
56 pancreatic resection
57 patient data
58 patients
59 poor prognosis
60 post-operative chemotherapy
61 prognosis
62 randomized study
63 randomized trials
64 recurrence
65 regimen
66 resection
67 results
68 setting
69 standard of care
70 standards
71 study
72 surgery
73 survival
74 survival advantage
75 survival differences
76 systemic disease
77 therapy
78 trials
79 use
80 schema:name Adjuvant Chemotherapy in Pancreatic Cancer
81 schema:pagination 1051-1077
82 schema:productId Nd7e8837ccca8438bb8c9091bba462821
83 Nebbd202acbae4ffabefc2d647cbc10eb
84 schema:publisher N9a321615132c4ef48c225bf5fbc93dd7
85 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041488623
86 https://doi.org/10.1007/978-0-387-77498-5_43
87 schema:sdDatePublished 2022-11-24T21:15
88 schema:sdLicense https://scigraph.springernature.com/explorer/license/
89 schema:sdPublisher Ndcdf132beafa4ce8a756c239634ff1f8
90 schema:url https://doi.org/10.1007/978-0-387-77498-5_43
91 sgo:license sg:explorer/license/
92 sgo:sdDataset chapters
93 rdf:type schema:Chapter
94 N5b4b3db1102546fdb88a4a8b478fc301 rdf:first sg:person.07372440237.86
95 rdf:rest Nbcfe4ba93fc644718e09641ee780e2dc
96 N9a321615132c4ef48c225bf5fbc93dd7 schema:name Springer Nature
97 rdf:type schema:Organisation
98 Nba68e25e86864852b1f6192cd3d8a327 rdf:first sg:person.01320161130.16
99 rdf:rest rdf:nil
100 Nbcfe4ba93fc644718e09641ee780e2dc rdf:first sg:person.0750565077.18
101 rdf:rest Nba68e25e86864852b1f6192cd3d8a327
102 Nd080dc66b07246a38cdf4daf44787a35 schema:isbn 978-0-387-77497-8
103 978-0-387-77498-5
104 schema:name Pancreatic Cancer
105 rdf:type schema:Book
106 Nd7e8837ccca8438bb8c9091bba462821 schema:name dimensions_id
107 schema:value pub.1041488623
108 rdf:type schema:PropertyValue
109 Ndcdf132beafa4ce8a756c239634ff1f8 schema:name Springer Nature - SN SciGraph project
110 rdf:type schema:Organization
111 Nebbd202acbae4ffabefc2d647cbc10eb schema:name doi
112 schema:value 10.1007/978-0-387-77498-5_43
113 rdf:type schema:PropertyValue
114 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
115 schema:name Medical and Health Sciences
116 rdf:type schema:DefinedTerm
117 anzsrc-for:1112 schema:inDefinedTermSet anzsrc-for:
118 schema:name Oncology and Carcinogenesis
119 rdf:type schema:DefinedTerm
120 sg:person.01320161130.16 schema:affiliation grid-institutes:grid.424926.f
121 schema:familyName Cunningham
122 schema:givenName David
123 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01320161130.16
124 rdf:type schema:Person
125 sg:person.07372440237.86 schema:affiliation grid-institutes:grid.415970.e
126 schema:familyName Ghaneh
127 schema:givenName Paula
128 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.07372440237.86
129 rdf:type schema:Person
130 sg:person.0750565077.18 schema:affiliation grid-institutes:grid.415970.e
131 schema:familyName Neoptolemos
132 schema:givenName John P.
133 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0750565077.18
134 rdf:type schema:Person
135 grid-institutes:grid.415970.e schema:alternateName Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK
136 schema:name Division of Surgery and Oncology School of Cancer Studies, University of Liverpool Royal Liverpool University Hospital, Liverpool, UK
137 rdf:type schema:Organization
138 grid-institutes:grid.424926.f schema:alternateName The Royal Marsden Hospital, London and Surrey, UK
139 schema:name The Royal Marsden Hospital, London and Surrey, UK
140 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...